Evidence map›Paper›PMID 41575165›Full record

Observational studyThe Journal of international medical research2026

Hematopoietic stem cell transplantation for multiple myeloma in Kazakhstan: Ten-year single-center experience.

Vadim Kemaykin, Zhandos Burkitbayev, Azat Karabekov, Olga Kolesnikova, Gulnur Zhakhina, Jamilya Saparbay, Ruzal Vildanova, Aigerim Idrisova, Dinara Zharlyganova, Zhuldyz Kuanysh

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in The Journal of international medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Vadim KemaykinCenter for Oncohematology and Bone Marrow Transplantation, National Research Oncology Center, Kazakhstan.
Zhandos BurkitbayevChairman of the Board, National Research Oncology Center, Kazakhstan.
Azat KarabekovCenter for Oncohematology and Bone Marrow Transplantation, National Research Oncology Center, Kazakhstan.
Olga KolesnikovaCenter for Oncohematology and Bone Marrow Transplantation, National Research Oncology Center, Kazakhstan.
Gulnur ZhakhinaSchool of Medicine, Nazarbayev University, Kazakhstan.
Jamilya SaparbayCenter for Hepatopancreatobiliary Surgery, Oncohepatology and Organ Transplantation, National Research Oncology Center, Kazakhstan.
Ruzal VildanovaCenter for Oncohematology and Bone Marrow Transplantation, National Research Oncology Center, Kazakhstan.
Aigerim IdrisovaCenter for Oncohematology and Bone Marrow Transplantation, National Research Oncology Center, Kazakhstan.
Dinara ZharlyganovaDepartment of Science, National Research Oncology Center, Kazakhstan.
Zhuldyz KuanyshDepartment of Science, National Research Oncology Center, Kazakhstan.ORCID 0000-0002-9578-4236

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ObjectiveThis study aimed to evaluate treatment patterns and clinical outcomes among patients with multiple myeloma treated at a major cancer center in Kazakhstan over a 10-year period.MethodsThis retrospective observational study analyzed data from 261 patients with multiple myeloma treated at the National Research Oncology Center, Astana, between 2010 and 2021. Sociodemographic and clinical characteristics, treatment regimens, and survival outcomes were assessed using data from electronic medical records.ResultsMost patients were diagnosed with stage II of multiple myeloma, based on the Durie-Salmon staging system, and the majority received bortezomib plus dexamethasone as first-line treatment. Hematopoietic stem cell transplantation was performed in 117 (45%) patients, with a 5-year overall survival rate of 63.6%, compared with 46.2% in patients who received chemotherapy alone.ConclusionsThe mean age of this cohort was 54 years, suggesting an earlier onset of multiple myeloma in the Kazakh population. Treatment regimens, stem cell yield, and post-transplant complications significantly influenced survival outcomes, underscoring the need to optimize transplant strategies and supportive care in Kazakhstan.

Indexed as

Hematopoietic Stem Cell TransplantationMultiple MyelomaAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBortezomibDexamethasoneFemaleHumansKazakhstanMaleMiddle AgedRetrospective StudiesSurvival RateTreatment OutcomeBortezomibDexamethasoneautologous hematopoietic stem cell transplantationblood cancerMultiple myelomasurvival analysis

Identifiers

PMID41575165
PMCPMC12833155

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.